When to Start a Statin Is a Preference-Sensitive Decision.
作者信息
Hayward Rodney A
机构信息
From Departments of Internal Medicine & Health Management and Policy, University of Michigan, Ann Arbor, MI; and Department of Veterans Affairs (VA) HSR&D Center for Clinical Management Research, VA Ann Arbor Healthcare System, MI.
出版信息
Circulation. 2017 Sep 19;136(12):1099-1101. doi: 10.1161/CIRCULATIONAHA.117.029808.
Abstract
摘要
相似文献
1
When to Start a Statin Is a Preference-Sensitive Decision.
Circulation. 2017 Sep 19;136(12):1099-1101. doi: 10.1161/CIRCULATIONAHA.117.029808.
2
Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
Circulation. 2017 Sep 19;136(12):1087-1098. doi: 10.1161/CIRCULATIONAHA.117.027067. Epub 2017 Jul 7.
3
Statins and the Classic Decision Analysis: Treat, Test, or Neither?
Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004688. doi: 10.1161/CIRCOUTCOMES.118.004688.
4
Cost effectiveness of statin therapy for the primary prevention of coronary heart disease.
Ir Med J. 2006 May;99(5):144-5.
5
Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
Circulation. 2007 May 8;115(18):2398-409. doi: 10.1161/CIRCULATIONAHA.106.667683. Epub 2007 Apr 23.
6
Long-term Cost-effectiveness of Statin Treatment for Primary Prevention of Cardiovascular Disease in the Elderly.
Cardiovasc Drugs Ther. 2015 Apr;29(2):187-97. doi: 10.1007/s10557-015-6584-7.
7
Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.
Atherosclerosis. 2015 Mar;239(1):240-7. doi: 10.1016/j.atherosclerosis.2014.12.059. Epub 2015 Jan 14.
8
Statins for cardiovascular prevention according to different strategies: a cost analysis.
Am J Cardiovasc Drugs. 2011;11(1):33-44. doi: 10.2165/11586760-000000000-00000.
9
Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
Eur Heart J. 2001 May;22(9):751-61. doi: 10.1053/euhj.2000.2308.
10
[Statins in primary prevention: how to share the decision?].
Rev Med Suisse. 2015 Nov 25;11(496):2222-6.
引用本文的文献
1
The Need for Brevity During Shared Decision Making (SDM) for Cancer Screening: Veterans' Perspectives on an "Everyday SDM" Compromise.
MDM Policy Pract. 2021 Oct 26;6(2):23814683211055120. doi: 10.1177/23814683211055120. eCollection 2021 Jul-Dec.
2
Guideline Concordance of Statin Treatment Decisions: A Retrospective Cohort Study.
J Clin Med. 2020 Nov 19;9(11):3719. doi: 10.3390/jcm9113719.
本文引用的文献
1
Evaluating the Impact and Cost-Effectiveness of Statin Use Guidelines for Primary Prevention of Coronary Heart Disease and Stroke.
Circulation. 2017 Sep 19;136(12):1087-1098. doi: 10.1161/CIRCULATIONAHA.117.027067. Epub 2017 Jul 7.
2
New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines.
Ann Intern Med. 2016 Dec 6;165(11):827-828. doi: 10.7326/L16-0417.
3
A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention.
Evid Based Med. 2015 Oct;20(5):162-9. doi: 10.1136/ebmed-2015-110170. Epub 2015 Jul 14.
4
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
JAMA. 2015 Jul 14;314(2):142-50. doi: 10.1001/jama.2015.6822.
5
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
JAMA Intern Med. 2014 Aug;174(8):1227-34. doi: 10.1001/jamainternmed.2014.2894.
6
Moneyball, gambling, and the new cholesterol guidelines.
Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):311-4. doi: 10.1161/CIRCOUTCOMES.114.000876. Epub 2014 Mar 4.
7
Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):268-75. doi: 10.1161/CIRCOUTCOMES.110.959239. Epub 2011 Apr 12.
8
Optimizing statin treatment for primary prevention of coronary artery disease.
Ann Intern Med. 2010 Jan 19;152(2):69-77. doi: 10.7326/0003-4819-152-2-201001190-00004.
9
The relative merits of population-based and targeted prevention strategies.
Milbank Q. 2008 Dec;86(4):557-80. doi: 10.1111/j.1468-0009.2008.00534.x.
10
Clinical decision making: from theory to practice. Designing a practice policy. Standards, guidelines, and options.
JAMA. 1990 Jun 13;263(22):3077, 3081, 3084. doi: 10.1001/jama.263.22.3077.
Zotero 插件